Christian Peschel

Summary

Affiliation: Klinikum rechts der Isar
Country: Germany

Publications

  1. ncbi request reprint Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use
    Wolfgang A Weber
    Nuklearmedizinische Klinik, Klinikum rechts der Isar, Ismaning Strabetae 22, 81675 Munchen, Germany
    J Clin Oncol 21:2651-7. 2003
  2. pmc Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven,
    Raymund Buhmann
    Department of Medicine III, Klinikum der Universitaet Muenchen, Grosshadern, Marchioninistrasse 15, Munich 81377, Germany
    J Transl Med 11:160. 2013
  3. pmc Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Birgit Luber
    Institut für allgemeine Pathologie und pathologische Anatomie, Technische Universitat Munchen, Trogerstraße 18, 81675 Munchen, Germany
    BMC Cancer 11:509. 2011
  4. pmc Myc suppression of Nfkb2 accelerates lymphomagenesis
    Ulrich Keller
    III Medical Department, Technische Universitat Munchen, Munich, Germany
    BMC Cancer 10:348. 2010
  5. ncbi request reprint Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer
    Christian Peschel
    Technische Universitat, III Medizinische Klinik, Munchen, Germany
    Lung Cancer 60:374-80. 2008
  6. ncbi request reprint Expression of cyclin E in resting and activated B-chronic lymphocytic leukaemia cells: cyclin E/cdk2 as a potential therapeutic target
    Thomas Decker
    IIIrd Department of Medicine, Technical University of Munich, Ismaninger Strasse 15, 81675 Munich, Germany
    Br J Haematol 125:141-8. 2004
  7. ncbi request reprint Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins
    Thomas Decker
    III Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Blood 103:2718-26. 2004
  8. ncbi request reprint [Structured patient education in oncology. A prospective study for implementing and effectiveness of interdisciplinary psycho-educational group intervention at a German university clinic]
    Florian Lordick
    III Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, TU Munchen
    Med Klin (Munich) 97:449-54. 2002
  9. doi request reprint Antiapoptotic effect of interleukin-2 (IL-2) in B-CLL cells with low and high affinity IL-2 receptors
    Thomas Decker
    Third Department of Medicine, Technical University of Munich, Munich, Germany
    Ann Hematol 89:1125-32. 2010
  10. ncbi request reprint [Interdisciplinary psychoeducational intervention by oncologists proved helpful for cancer patients]
    Harald Gündel
    Institut und Poliklinik für Psychosomatische Medizin, Psychotherapie und Medizinische Psychologie, TU Munchen, Klinikum rechts der Isar, Langerstr 3, 81675 Munchen, Germany
    Z Psychosom Med Psychother 49:246-61. 2003

Collaborators

Detail Information

Publications68

  1. ncbi request reprint Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use
    Wolfgang A Weber
    Nuklearmedizinische Klinik, Klinikum rechts der Isar, Ismaning Strabetae 22, 81675 Munchen, Germany
    J Clin Oncol 21:2651-7. 2003
    ..To prospectively evaluate the use of positron emission tomography with the glucose analog fluorodeoxyglucose (FDG-PET) to predict response to chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC)...
  2. pmc Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven,
    Raymund Buhmann
    Department of Medicine III, Klinikum der Universitaet Muenchen, Grosshadern, Marchioninistrasse 15, Munich 81377, Germany
    J Transl Med 11:160. 2013
    ..Hence, FBTA05 may maximize GVL effects by simultaneously decreasing the incidence and severity of GVHD...
  3. pmc Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Birgit Luber
    Institut für allgemeine Pathologie und pathologische Anatomie, Technische Universitat Munchen, Trogerstraße 18, 81675 Munchen, Germany
    BMC Cancer 11:509. 2011
    ....
  4. pmc Myc suppression of Nfkb2 accelerates lymphomagenesis
    Ulrich Keller
    III Medical Department, Technische Universitat Munchen, Munich, Germany
    BMC Cancer 10:348. 2010
    ..The Rel/NF-kappaB family member NFKB2 is altered by chromosomal translocations or deletions in lymphoid malignancies and deletion of the C-terminal ankyrin domain of NF-kappaB2 augments lymphocyte proliferation...
  5. ncbi request reprint Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer
    Christian Peschel
    Technische Universitat, III Medizinische Klinik, Munchen, Germany
    Lung Cancer 60:374-80. 2008
    ..v. infusion at a dose of 5mg/m(2), every 2 weeks, to patients with chemotherapy pretreated advanced non-small cell lung cancer (NSCLC)...
  6. ncbi request reprint Expression of cyclin E in resting and activated B-chronic lymphocytic leukaemia cells: cyclin E/cdk2 as a potential therapeutic target
    Thomas Decker
    IIIrd Department of Medicine, Technical University of Munich, Ismaninger Strasse 15, 81675 Munich, Germany
    Br J Haematol 125:141-8. 2004
    ..We conclude that further evaluation of cyclin E and p27 in peripheral blood cells might help to identify prognostic subgroups. In addition, inhibition of Cyclin E-cdk2 activity by Roscovitine might be a new therapeutic strategy in B-CLL...
  7. ncbi request reprint Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins
    Thomas Decker
    III Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Blood 103:2718-26. 2004
    ..HA22 was more active than BL22. In conclusion, these immunotoxins induce caspase-mediated apoptosis involving mitochondrial damage. Combination with chemotherapy is expected to improve the efficacy of immunotoxin treatment...
  8. ncbi request reprint [Structured patient education in oncology. A prospective study for implementing and effectiveness of interdisciplinary psycho-educational group intervention at a German university clinic]
    Florian Lordick
    III Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, TU Munchen
    Med Klin (Munich) 97:449-54. 2002
    ..To identify the target group for a structured educational group intervention in an acute cancer care setting, and to prove its effectiveness...
  9. doi request reprint Antiapoptotic effect of interleukin-2 (IL-2) in B-CLL cells with low and high affinity IL-2 receptors
    Thomas Decker
    Third Department of Medicine, Technical University of Munich, Munich, Germany
    Ann Hematol 89:1125-32. 2010
    ..IL-2 might be an important survival factor in activated B-CLL cells and might contribute to disease progression by upregulation of several critical antiapoptotic proteins...
  10. ncbi request reprint [Interdisciplinary psychoeducational intervention by oncologists proved helpful for cancer patients]
    Harald Gündel
    Institut und Poliklinik für Psychosomatische Medizin, Psychotherapie und Medizinische Psychologie, TU Munchen, Klinikum rechts der Isar, Langerstr 3, 81675 Munchen, Germany
    Z Psychosom Med Psychother 49:246-61. 2003
    ..We prospectively evaluated the effects of a six-session psychoeducational intervention held by medical doctors or psychologists in a German acute cancer center setting...
  11. ncbi request reprint Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin
    Thomas Decker
    3rd Department of Medicine, Technical University of Munich, Germany
    Blood 101:278-85. 2003
    ..We conclude from our study that rapamycin might be an attractive substance for therapy for B-CLL patients by inducing a G(1) arrest in proliferating tumor cells...
  12. ncbi request reprint Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells
    Christian Bogner
    IIIrd Department of Medicine, Technical University of Munich, Ismaningerstrasse 15, 81675, Munich, Germany
    Ann Hematol 85:458-62. 2006
    ....
  13. doi request reprint Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression
    Christian Bogner
    IIIrd Department of Medicine, Technical University of Munich, Munich, Germany
    Br J Haematol 148:99-109. 2010
    ..Our results were confirmed in freshly isolated MCL-cells from patients with leukaemic MCL. We conclude that Bcl-2 expression is important for mediating resistance against the immunotoxin BL22 in MCL cells...
  14. ncbi request reprint Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity
    Olaf Gross
    III Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Ismaninger Str 22, 81675 Munich, Germany
    Nature 442:651-6. 2006
    ..Thus, our results define a novel innate immune pathway and indicate that evolutionarily distinct ITAM receptors in innate and adaptive immune cells use diverse adaptor proteins to engage selectively the conserved Bcl10-Malt1 module...
  15. pmc Multiple ITAM-coupled NK-cell receptors engage the Bcl10/Malt1 complex via Carma1 for NF-kappaB and MAPK activation to selectively control cytokine production
    Olaf Gross
    III Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Blood 112:2421-8. 2008
    ....
  16. doi request reprint Novel markers of mesenchymal stem cells defined by genome-wide gene expression analysis of stromal cells from different sources
    Nikolas Kaltz
    3rd Department of Internal Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany
    Exp Cell Res 316:2609-17. 2010
    ..Our observations may facilitate the study of lineage relationships in MSC as well as facilitate the development of more homogeneous cell populations for mesenchymal cell therapy...
  17. ncbi request reprint Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab
    Kathrin Wanner
    IIIrd Department of Medicine, Technical University of Munich, Munich, Germany
    Br J Haematol 134:475-84. 2006
    ..mTOR inhibition is a promising therapeutic strategy in DLBCL by inducing a G1 arrest and augments rituximab-induced cytotoxicity. Therefore, combination of these drugs might be an interesting new therapeutic approach in DLBCL patients...
  18. ncbi request reprint Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer
    Verena Voelter
    Centre Hospitalier Universitaire Vaudois, Multidisciplinary Oncology Center, Lausanne, Switzerland
    Ann Thorac Surg 78:1037-41. 2004
    ..Patients who are treated with neoadjuvant chemotherapy with a curative intent are exposed to toxicity that may negatively affect their future outcome...
  19. ncbi request reprint Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer
    Jean Yves Douillard
    Centre Rene Gauducheau, Nantes, France
    Lung Cancer 46:361-8. 2004
    ....
  20. ncbi request reprint Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma
    Kathrin Abbrederis
    Third Department of Medicine Hematology Oncology, Institute for Medical Statistics and Epidemiology, and Munich Center for Clinical Studies, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    Ann Thorac Surg 82:293-7. 2006
    ..In a previous study we showed that many patients with esophagogastric adenocarcinoma experience anemia during neoadjuvant chemotherapy. We now investigated the role of erythropoietin in managing anemia during neoadjuvant chemotherapy...
  21. ncbi request reprint Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18
    Natasha B Leighl
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Canada
    J Clin Oncol 23:2831-9. 2005
    ..In early phase studies, BMS- 275291 was not associated with dose-limiting joint toxicity seen with other MMPIs...
  22. ncbi request reprint Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways
    Christian Bogner
    IIIrd Department of Medicine, Technical University of Munich, Munich, Germany
    Exp Hematol 31:218-25. 2003
    ..Lactacystin is a specific inhibitor of the proteasome and is a potent apoptosis inductor in resting peripheral B-CLL cells. In the present study, we investigated the effect of proteasome inhibition in proliferating B-CLL cells...
  23. ncbi request reprint Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides
    Thomas Decker
    3rd Department of Medicine, Technical University of Munich, Munich, Germany
    Blood 99:1320-6. 2002
    ..In summary, immunostimulatory CpG-ODNs efficiently sensitize B-CLL cells to a recombinant immunotoxin by modulation of its target. This new treatment strategy deserves further attention...
  24. ncbi request reprint Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells
    Christian Bogner
    Third Department of Medicine, Technical University of Munich, Munich, Germany
    Br J Haematol 122:260-8. 2003
    ..fmk. Lactacystin was also effective in inducing apoptosis in lymphoma cells from MCL patients. We conclude that inhibition of the proteasome might be a promising therapeutic approach for this incurable disease...
  25. ncbi request reprint Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens
    Julia Neudorfer
    Department of Hematology Oncology, Klinikum rechts der Isar, Technical University of Munich, Germany
    J Immunol Methods 320:119-31. 2007
    ....
  26. ncbi request reprint Bcl10/Malt1 signaling is essential for TCR-induced NF-kappaB activation in thymocytes but dispensable for positive or negative selection
    Philipp J Jost
    Third Medical Department, Technical University of Munich, Klinikum rechts der Isar, Ismaninger Strasse 22, 81675 Munich, Germany
    J Immunol 178:953-60. 2007
    ..Thus, while TCR signaling to NF-kappaB controls the activation of mature T cells, we suggest that this pathway is not involved in the positive or negative selection of thymocytes...
  27. pmc Bcl10 and Malt1 control lysophosphatidic acid-induced NF-kappaB activation and cytokine production
    Stefanie Klemm
    Third Medical Department, Technical University of Munich, Klinikum rechts der Isar, Ismaninger Strasse 22, 81675 Munich, Germany
    Proc Natl Acad Sci U S A 104:134-8. 2007
    ..Thus, our results identify a NF-kappaB-inducing signaling pathway downstream of GPCRs and reveal previously unrecognized functions for Bcl10/Malt1 signaling in nonimmune cells...
  28. ncbi request reprint Cell cycle inhibition in malignant lymphoma: disease control by attacking the cellular proliferation machinery
    Ingo Ringshausen
    Comprehensive Cancer Center, University of California, San Francisco, 2340 Sutter Street, San Francisco, CA 94115, USA
    Curr Drug Targets 7:1349-59. 2006
    ..Furthermore, we provide an overview of novel direct and indirect cell cycle inhibitors and their impact on the treatment of patients with B cell lymphomas...
  29. ncbi request reprint Bone marrow involvement in follicular lymphoma: comparison of histology and flow cytometry as staging procedures
    Burkhard Schmidt
    Department of Hematology and Oncology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Strasse 22, 81675 Munich, Germany
    Leuk Lymphoma 47:1857-62. 2006
    ..Due to the lower false negative rate, trephine BM biopsy remains crucial for the detection of BM involvement in FL...
  30. ncbi request reprint The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens
    Florian Scheich
    Department of Hematology Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    Blood 110:2556-60. 2007
    ..These results encourage the development of immunotherapeutic approaches against Bcr-Abl-regulated antigens for the treatment of CML patients with residual disease following therapy with Bcr-Abl kinase inhibitors...
  31. ncbi request reprint Peripheral primitive neuroectodermal tumor of the stomach in a 14-year-old boy: a case report
    Ralph Czekalla
    Second Department of Medicine, Bogenhausen Academic Teaching Hospital, Munich, Germany
    Eur J Gastroenterol Hepatol 16:1391-400. 2004
    ..Because of the tumour's intense expression of CD117 (c-kit), the patient is now treated with the tyrosine kinase inhibitor imatinib (STI571)...
  32. ncbi request reprint Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome
    Joerg R Siewert
    Department of Surgery, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Ann Surg 246:624-8; discussion 628-31. 2007
    ..To study the impact of induction chemotherapy on surgical risk and outcome in locally advanced Barrett cancer...
  33. doi request reprint Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: analysis of remission induction and stem cell mobilization
    Helge Menzel
    III Medical Department, Technical University Munich, Munich, Germany
    Leuk Lymphoma 49:1337-44. 2008
    ..The addition of rituximab to IEV salvage chemotherapy increases the response rates in B-cell NHL without affecting stem cell mobilization, but overall survival for patients proceeding to high-dose chemotherapy is not improved...
  34. ncbi request reprint Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG
    Ambros J Beer
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 49:22-9. 2008
    ..We evaluated whether assessment of alpha(v)beta(3) expression and of glucose metabolism with PET using (18)F-galacto-RGD and (18)F-FDG provides complementary information in cancer patients...
  35. ncbi request reprint Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta
    Ingo Ringshausen
    Third Department of Medicine, Technical University of Munich, Germany
    Blood 100:3741-8. 2002
    ..We conclude that activated PI-3K might be important in the pathogenesis of B-CLL, and survival signals might be mediated via PKCdelta. Therefore, inhibition of PI-3K or PKCdelta may be an innovative approach to treat B-CLL...
  36. ncbi request reprint Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells
    Katharina S Götze
    Haematologica 92:1282-3. 2007
    ..The clinical course suggests caution when using newer immunosuppressive drugs for treatment of CLL, especially in the context of additional purine analog therapy...
  37. ncbi request reprint PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
    Florian Lordick
    Department of Surgery, Clinic rechts der Isar, Technical University of Munich, Munich, Germany
    Lancet Oncol 8:797-805. 2007
    ..We aimed to assess the feasibility of a PET-response-guided treatment algorithm and its potential effect on prognosis...
  38. doi request reprint GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituximab treatment
    Christian Meyer Zum Buschenfelde
    III Medical Department, Klinikum rechts der Isar, Technical University Munich, Munich, Germany
    Cancer Res 68:5414-22. 2008
    ..These data show the importance of membrane microdomains in the effect of rituximab and may offer a predictive factor for the responsiveness of lymphoma cells to rituximab...
  39. ncbi request reprint MALT1 directs B cell receptor-induced canonical nuclear factor-kappaB signaling selectively to the c-Rel subunit
    Uta Ferch
    Third Medical Department, Technical University of Munich, Klinikum rechts der Isar, 81675 Munich, Germany
    Nat Immunol 8:984-91. 2007
    ..Our results provide mechanistic insights into B cell receptor-induced survival and proliferation signals and demonstrate the selective control of c-Rel in the canonical NF-kappaB pathway...
  40. ncbi request reprint CD133-enriched CD34(-) (CD33/CD38/CD71)(-) cord blood cells acquire CD34 prior to cell division and hematopoietic activity is exclusively associated with CD34 expression
    Katharina S Götze
    3rd Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    Exp Hematol 35:1408-14. 2007
    ..In conclusion, we demonstrate that CD133-enriched Lin(-)CD34(-) cord blood cells acquire CD34 prior to cell division and that long-term hematopoietic activity is associated exclusively with expression of CD34...
  41. ncbi request reprint Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma
    Ken Herrmann
    Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
    Clin Cancer Res 13:3552-8. 2007
    ....
  42. ncbi request reprint Multisite phosphorylation of nuclear interaction partner of ALK (NIPA) at G2/M involves cyclin B1/Cdk1
    Florian Bassermann
    Department of Internal Medicine III, Technical University of Munich, 81675 Munich, Germany, and Department of Pathology, St Jude Chidren s Research Hospital, Memphis, TN 38105, USA
    J Biol Chem 282:15965-72. 2007
    ..Thus, cyclin B1/Cdk1 may contribute to the regulation of its own abundance in early mitosis...
  43. ncbi request reprint Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy
    Markus Schwaiger
    Nuklearmedizinische Klinik und Poliklinik, Klinikum r d Isar der Technischen Universität München, Ismaninger Str 22, 81675, Munich, Germany
    Eur J Nucl Med Mol Imaging 33:1-5. 2006
  44. ncbi request reprint Is lanreotide and/or interferon alfa an adequate therapy for neuroendocrine tumors?
    Verena Völter
    J Clin Oncol 22:573; author reply 574-5. 2004
  45. ncbi request reprint Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro
    Kristina Fleischer
    Department of Hematology Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaningerstrasse 22, D 81675 Munich, Germany
    J Immunol 172:162-9. 2004
    ....
  46. ncbi request reprint Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors
    Nikolas von Bubnoff
    Department of Internal Medicine III, Technical University of Munich, Trogerstrasse 32, D 81675 Munich, Germany
    Cancer Res 63:6395-404. 2003
    ....
  47. ncbi request reprint Sustained expansion and transgene expression of coagulation factor VIII-transduced cord blood-derived endothelial progenitor cells
    Christian Herder
    Institute for Transfusion Medicine and Immunohematology, Red Cross Blood Donor Service Baden Württemberg Hessen, Sandhofstr 1, 60528 Frankfurt am Main, Germany
    Arterioscler Thromb Vasc Biol 23:2266-72. 2003
    ..In this study, we tested the capacity of cord blood-derived endothelial progenitor cells (CBECs) for FVIII expression on stable lentiviral transduction...
  48. ncbi request reprint Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway
    Florian Bassermann
    Department of Internal Medicine III, Laboratory of Leukemogenesis, Technical University of Munich, 81675, Germany
    J Biol Chem 277:12437-45. 2002
    ....
  49. ncbi request reprint Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA)
    Tao Ouyang
    Department of Internal Medicine III, Laboratory of Leukemogenesis, Technical University of Munich, 81675 Munich, Germany
    J Biol Chem 278:30028-36. 2003
    ..These results implicate an antiapoptotic role for NIPA in NPM-ALK-mediated signaling events...
  50. ncbi request reprint Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor
    Rebekka Grundler
    Department of Internal Medicine III, Laboratory of Leukemogenesis, Technical University of Munich, Germany
    Blood 102:646-51. 2003
    ..These results suggest that it may be useful to determine the exact kind of FLT3 mutation when applying receptor kinase inhibitors in clinical trials...
  51. ncbi request reprint Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma
    Klemens Scheidhauer
    Klinik und Poliklinik fur Nuklearmedizin, Klinikum rechts der Isar, Technische Universitat Munchen, Ismaninger Strasse 22, 81675 Munich, Germany
    Eur J Nucl Med Mol Imaging 29:1276-82. 2002
    ..The therapeutic activities of (131)I-labelled rituximab required to deliver similar doses should be lower than those of its murine counterpart...
  52. ncbi request reprint Restoration of transgene expression in hematopoietic cells with drug-selectable marker genes
    Thomas Licht
    Department of Hematology Oncology, Klinikum rechts der Isar, Technical University of Munich Medical Center, Munich, Germany
    Curr Gene Ther 2:227-34. 2002
    ..With the use of bicistronic vectors, expression and function of therapeutic genes have been increased in tissue culture and in animal models. Further preclinical investigations are needed to identify optimal conditions for selection...
  53. ncbi request reprint Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain
    Thomas Jahn
    Department of Internal Medicine III, Laboratory of Leukemogenesis, Technical University of Munich, Germany
    Oncogene 21:4508-20. 2002
    ....
  54. ncbi request reprint Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
    Charles L Sawyers
    Department of Medicine and Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA
    Blood 99:3530-9. 2002
    ..Additional clinical studies are warranted to explore the efficacy and feasibility of imatinib used in combination with other antileukemic drugs...
  55. ncbi request reprint A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor
    Nikolas von Bubnoff
    Department of Internal Medicine III, Technical University of Munich, D 81675 Munich, Germany
    Blood 105:1652-9. 2005
    ..Thus, this robust and simple screening system provides a rational basis for combinatorial and sequential treatment strategies in targeted cancer therapy...
  56. ncbi request reprint Isolation and expansion of tumor-reactive cytotoxic T-cell clones for adoptive immunotherapy
    Helga Bernhard
    Department of Hematology Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    Methods Mol Med 109:175-84. 2005
    ..Tumor-reactive T-cells retain the functional activity in terms of cytolysis after expansion, encouraging their use in the immunotherapy of cancer patients...
  57. pmc The Bcl10-Malt1 complex segregates Fc epsilon RI-mediated nuclear factor kappa B activation and cytokine production from mast cell degranulation
    Stefanie Klemm
    Third Medical Department, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany
    J Exp Med 203:337-47. 2006
    ..Thus, Bcl10 and Malt1 are essential positive mediators of FcepsilonRI-dependent mast cell activation that selectively uncouple NF-kappaB-induced proinflammatory cytokine production from degranulation and leukotriene synthesis...
  58. ncbi request reprint Antibody-based targeted therapy for gastric cancer
    Florian Lordick
    Gastric Cancer 8:206-8. 2005
  59. ncbi request reprint Mitotic entry: a matter of oscillating destruction
    Florian Bassermann
    Department of Internal Medicine III, Technical University of Munich, Munich, Germany
    Cell Cycle 4:1515-7. 2005
    ..Thus, oscillating ubiquitination of nuclear cyclin B1 driven by the SCFNIPA complex contributes to the timing of mitotic entry in the mammalian cell cycle...
  60. ncbi request reprint Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells
    Susanne Hipp
    Haematologica 90:1433-4. 2005
    ..The mTOR inhibitor, rapamycin, inhibited proliferation in three mantle cell lymphoma (MCL) cell lines and reduced cyclin D3 expression while cyclin D1 levels remained unchanged. This finding was confirmed in cells from a MCL patient...
  61. ncbi request reprint NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry
    Florian Bassermann
    Department of Internal Medicine III, Technical University of Munich, 81675 Munich, Germany
    Cell 122:45-57. 2005
    ..Thus, SCF(NIPA)-based ubiquitination may regulate S-phase completion and mitotic entry in the mammalian cell cycle...
  62. ncbi request reprint Long-term maintenance of hematopoietic stem cells does not require contact with embryo-derived stromal cells in cocultures
    Robert A J Oostendorp
    Department of Cell Biology and Genetics, Erasmus University, Rotterdam, Netherlands
    Stem Cells 23:842-51. 2005
    ..In summary, we show for the first time long-term maintenance of adult bone marrow HSCs in stroma noncontact cultures and identify some secreted molecules that may be involved in this support...
  63. ncbi request reprint Radiotherapy and chemotherapy for myoepithelioma of the sellar region
    Carsten Nieder
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Germany
    Strahlenther Onkol 181:260-3. 2005
    ..Myoepithelioma might arise in the head and neck area, especially within the salivary glands. It is very uncommon as a primary intracranial tumor...
  64. ncbi request reprint Endothelial-like cells expanded from CD34+ blood cells improve left ventricular function after experimental myocardial infarction
    Ilka Ott
    I Department of Medicine, Technical University Munich, Munich, Germany
    FASEB J 19:992-4. 2005
    ..Therefore, in vitro expanded EPC-derived endothelial cells may be beneficial in the treatment of ischemic disease...
  65. ncbi request reprint A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment
    Nikolas von Bubnoff
    Department of Internal Medicine III, Technical University of Munich, Munich, Germany
    Cell Cycle 4:400-6. 2005
    ..We here provide a detailed methodological description, and discuss the implications of this strategy for different clinically relevant oncogenic tyrosine kinases...
  66. ncbi request reprint Phosphorylation of grb10 regulates its interaction with 14-3-3
    Susanne Urschel
    Department of Internal Medicine III, Laboratory of Leukemogenesis, Technical University of Munich, 81675 Munich, Germany
    J Biol Chem 280:16987-93. 2005
    ..Based on these findings, we propose a regulatory circuitry involving a phosphorylation-regulated complex formation of Grb10 with 14-3-3 and Akt...
  67. ncbi request reprint Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma
    Agnieszka Korfel
    Department of Haematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Br J Haematol 128:177-83. 2005
    ..2 vs. 9.9 months, P = 0.02). Median survival was significantly longer at institutions accruing at least four patients than at those with fewer patients (31.5 vs. 9.5 months, P = 0.03)...
  68. ncbi request reprint Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells
    Christian Meyer Zum Büschenfelde
    Department of Hematology Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaningerstrasse 22, D 81675 Munich, Germany
    Cancer Res 62:2244-7. 2002
    ..The potentially synergistic activity of HER2-specific antibody and CTL encourages the development of an HER2-targeted immunotherapy using a combination of inhibitory antibodies and CTLs for patients with HER2-overexpressing tumors...